Omada Health funding, valuation and investors

Overview

Omada Health delivers virtual care programs for chronic conditions including type 2 diabetes, hypertension, prediabetes, musculoskeletal pain, and behavioral health. Employers and health plans contract for Omada's coaching, connected devices, and app-based behavior change with outcomes reporting for value-based care. Founded in 2011, Omada was an early digital therapeutics pioneer. a16z led its Series B in 2014; Norwest Venture Partners was a long-time major investor. Omada priced its IPO at $19/share on Nasdaq (OMDA) in June 2025, with a16z holding roughly 8–10% pre-IPO per SEC filings and TechCrunch.

Why Omada Health is interesting

Digital health OG that survived a decade of payer pivots to IPO on Nasdaq (OMDA, Jun 2025) — a16z led Series B and held ~9% pre-IPO while Norwest stayed through the public listing.

Product & use cases

Omada combines human health coaches, mobile apps, and FDA-cleared or clinical-grade devices (scales, BP cuffs) to deliver employer- and plan-sponsored chronic disease management with measurable weight, glucose, and blood pressure outcomes.

• Employer wellness programs for diabetes prevention and management
• Health plan offerings to reduce chronic disease costs
• MSK virtual physical therapy as add-on benefit
• Behavioral health coaching integrated with metabolic programs

Key facts

• IPO (Jun 2025): priced $19/share on Nasdaq (OMDA) — TechCrunch, SEC 424B4
• Series B (2014): led by a16z — Forge, Business Insider
• a16z held ~8–10% pre-IPO per filing coverage
• Norwest Venture Partners long-time major backer
• Co-investors not in VCT directory: U.S. Venture Partners, Revelation Partners, Wellington Management

Funding history (newest first)

Investors in our directory

Funds linked from Omada Health's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Ten-plus years of outcomes data and payer relationships differentiate Omada from newer DTx startups; IPO capital supports scale vs point-solution competitors.

Employer-sponsored chronic care is crowded post-COVID with telehealth incumbents and GLP-1 tailwinds reshaping obesity spend. Omada's survival and IPO signal payer willingness to pay for longitudinal coaching vs one-off visits. Risk: margin pressure from larger telehealth platforms bundling similar programs.

• Virta Health direct

  Diabetes reversal via nutritional ketosis; different clinical approach, overlapping employer buyers.

• Livongo / Teladoc incumbent

  Teladoc acquired Livongo; combined chronic care and telehealth bundle competes for large employers.

• Vida Health direct

  Virtual cardiometabolic and mental health coaching; similar B2B2C distribution.

• Calibrate / WeightWatchers clinical adjacent

  GLP-1 era weight programs; overlap on obesity-related chronic care budgets.

Notable stories

• Omada waited more than a decade from founding (2011) to IPO (2025) — a rare digital health company that persisted through DTx hype cycles and payer skepticism.
• a16z's 2014 Series B bet on Omada predated the a16z Bio + Health split but aligned with later thesis on software-delivered care.

Industries

Market / IPO context